Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.40 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11271011 | 1.00 | CXCL8 (0.44) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL360635 | 0.98 | CXCL8 (0.45) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL28355542 | 0.89 | FPR2 (0.42) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL5007635 | 0.87 | GAA (0.43) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL27562422 | 0.86 | MEN1 (0.41) | CXCL8LMNAMEN1KMT2APTGS1 | |
| Trolamine SCHEMBL10993885 | 0.85 | CXCL8 (0.37) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL7165977 | 0.85 | OPRK1 (0.44) | CXCL8LMNAMEN1KMT2ACA1 | |
| SCHEMBL7574221 | 0.85 | ALDH1A1 (0.44) | MEN1KMT2ACA1CA2CYP2D6 | |
| SCHEMBL9350140 | 0.83 | PTGS1 (0.46) | CXCL8LMNAMEN1KMT2APTGS1 | |
| SCHEMBL7573697 | 0.83 | CAMK2A (0.44) | LMNAMEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0017169-B1 | IMPROVED ANTI-INFLAMMATORY COMBINATIONS HAVING REDUCED ULCEROGENICITY | MERCK & CO. INC. (US) | 1983-03-09 | — | — | EP | claimed |
| EP-0017169-A1 | Improved anti-inflammatory combinations having reduced ulcerogenicity | MERCK & CO. INC. (US) | 1980-10-15 | — | — | EP | claimed |
| JP-54160336-A | — | — | None | — | — | JP | disclosed |
| CN-109645007-B | C14H10Cl2NNaO2 is in preparation for preventing and treating the application in the fungicide by the microbial plant disease of pathogenic | 青岛农业大学 | 2019-08-13 | — | — | CN | disclosed |
| CN-109645007-A | C14H10Cl2NNaO2 is in preparation for preventing and treating the application in the fungicide by the microbial plant disease of pathogenic | 青岛农业大学 | 2019-04-19 | — | — | CN | disclosed |
| CN-109620821-A | C14H10Cl2NNaO2 is for the application in the pre-shrunk tracheal smooth muscle of diastole and treatment asthma | 中南民族大学 | 2019-04-16 | — | — | CN | disclosed |
| US-20040132814-A1 | Pharmaceutical compositions | LOEFROTH JAN-ERIK (SE) | 2004-07-08 | — | — | US | disclosed |
| US-20030194440-A1 | PHARMACEUTICAL COMPOSITION FOR SUSTAINED RELEASE OF THE HMG-COA REDUCTASE INHIBITOR FLUVASTATIN | NOVARTIS AG (CH) | 2003-10-16 | — | — | US | disclosed |
| EP-0948320-B1 | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN | NOVARTIS AG (CH) | 2003-04-09 | — | — | EP | disclosed |
| EP-1202620-A1 | ANTI-INFLAMMATORY THERAPY FOR INFLAMMATORY MEDIATED INFECTION | The Regents of the University of California (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2000069255-A1 | ANTI-INFLAMMATORY THERAPY FOR INFLAMMATORY MEDIATED INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-11-23 | — | — | WO | disclosed |
| EP-0825856-A4 | IRRITATION RELIEF USING NONSTEROIDAL ANTI-INFLAMMATORY COMPOUNDS | DISHLER JON (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0948320-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN | Astra Aktiebolag (SE) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998015264-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN | ASTRA AKTIEBOLAG (SE) | 1998-04-16 | — | — | WO | disclosed |
| EP-0825856-A1 | IRRITATION RELIEF USING NONSTEROIDAL ANTI-INFLAMMATORY COMPOUNDS | Dishler, Jon (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996033708-A1 | IRRITATION RELIEF USING NONSTEROIDAL ANTI-INFLAMMATORY COMPOUNDS | DISHLER JON (US) | 1996-10-31 | — | — | WO | disclosed |
| EP-0017169-A1 | Improved anti-inflammatory combinations having reduced ulcerogenicity | MERCK & CO. INC. (US) | 1980-10-15 | — | — | EP | disclosed |
| JP-S54160336-A | N-BENZYL-O-(2,6-DICHLOROANILINO)PHENYLACETIC ACID DERIVATIVE | NISSAN CHEM IND LTD | 1979-12-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132814-A1 | Pharmaceutical compositions | HMGCR, PCSK9, ABCB11 | CXCL8 2377/4885LMNA 1408/4885MEN1 1631/4885 |
| US-20030194440-A1 | PHARMACEUTICAL COMPOSITION FOR SUSTAINED RELEASE OF THE HMG-COA REDUCTASE INHIBITOR FLUVASTATIN | HMGCR, CYP11A1, PCSK9 | CXCL8 3111/4885LMNA 1263/4885MEN1 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.